• • Multiple myeloma patients receive fewer specialist palliative care services and experience higher odds of dying in hospital. • • Early identification of haematological patients in need of palliative care is hindered by prognostic models relying on indicators for solid cancers. • • These indicators do not work well due to the different entry-re-entry disease trajectory that myeloma patients experience. Identification of patients with palliative care needs should focus on assessing patient-reported symptoms and psychosocial well-being for identifying those at risk of deterioration.
Introduction
With treatment options and the introduction of novel anti-cancer agents, the lives of cancer patients have been lengthened, which in turn has changed the cancer trajectory, resulting in chronic disease patterns. [1] [2] [3] [4] One such cancer is multiple myeloma (MM), an incurable haematological malignancy of the bone marrow and one of the most common haematological cancers with incidences of 3.29-4.82 per 100,000 population. 5, 6 Multiple myeloma is primarily a disease of older age with a median age at time of diagnosis of 73 years and almost 40% of patients being 75 years or older. 7, 8 Myeloma results in bone destruction, bone marrow failure and renal impairment. 9 Throughout their disease trajectory, patients suffer from a variety of symptoms, some resulting from advancing disease, some being treatment side effects such as neuropathies. 10, 11 Unlike solid cancers, where relatively high levels of functioning are maintained up until a distinct and short period of terminal decline, 12 haematological malignancies often follow no such clear pattern. Trajectories rather show entry, reentry characteristics, with periods of intensive antineoplastic regimens that may continue until the end of life, hospitalisations due to treatment complications, interspersed with stable, treatment-free intervals. [13] [14] [15] [16] [17] These characteristics make determination of palliative status and referral to Specialist palliative care difficult. Haematologists in Australia and the United Kingdom have expressed insecurities regarding when referral is appropriate. 17, 18 Therefore, haematological cancer patients still miss out on Specialist palliative care, as evidenced by a metaanalysis showing that the number of referrals to Specialist palliative care is much lower in this cancer group than in solid tumours. 19 Patients with a haematological cancer have 2.25 times the odds of dying in hospital. 20, 21 Even if Specialist palliative care is initiated, it is often done too late in the disease trajectory. 20, 21 However, early integration of palliative care as a new model can only be achieved by knowing which patients are in need of such receipt of care. Prognostic indicators for predicting survival and therefore initiation of palliative care have been based on clinical features, laboratory data, and response to treatment. [22] [23] [24] One of the most interesting findings in recent years has been the evidence for the independent prognostic role of patientreported outcomes. [25] [26] [27] [28] This could help identify those with poor quality of life (QOL) that would benefit from early palliative care involvement.
The main aim of our study was to identify distinct trajectories of health-related Quality of life (HRQOL) over 8 months in patients with Multiple myeloma of all stages, and to determine demographic and clinical characteristics predicting declining or poor Health related quality of life . It was hypothesised that a high symptom burden together with a more advanced disease stage, higher comorbidity level and a lower Eastern Cooperative Oncology Group (ECOG) performance status would predict inclusion in classes with poor or deteriorating Quality of life.
Methods
For this multi-centre, longitudinal prospective study, patients with Multiple myeloma were recruited from both inpatient stem cell transplantation units and outpatient haematology clinics or chemotherapy day care centres in 14 secondary and tertiary hospitals in England, United Kingdom, from February to August 2013. The study protocol and procedures were approved by the Central London Research Ethics Committee (study ref number: 13/LO/1140). Further local Research and Development approvals were obtained from all 14 participating National Health Service (NHS) hospital trusts. The study was conducted according to the principles expressed in the Declaration of Helsinki. All participants were given full information regarding the study, signed to indicate their consent and could withdraw at any time without giving reasons or withdrawal affecting their medical treatment. All information was kept confidential.
Participants and procedures
Consecutive patients were screened by a member of the clinical team for eligibility according to study entry criteria at all the participating sites. Eligibility criteria were designed to identify people at various stages of their disease rather than focusing on a cohort at the end-of-life/ impending death to allow greater representativeness than focusing on treatment samples. Eligibility criteria were adult patients with confirmed diagnosis of Multiple myeloma that had been disclosed to the patient, and capacity to give informed written consent. Patients who were too unwell, distressed or symptomatic to participate as judged by their main clinical team member were excluded, as were patients with severe neutropenia or for whom myeloma was not the most important health problem.
All patients screened eligible were asked permission by the clinical staff to being approached by a study nurse or research. The study questionnaires were completed either during the clinic visit or at home with patients being supplied a prepaid envelope for returning the questionnaire to the institute. Participants received one written reminder and an additional telephone call if they did not return their questionnaire within 2 weeks.
Among the disease details, the date of diagnosis and the immunoglobulin type (Ig) were extracted, alongside time since diagnosis and stage according to the International Staging System (ISS). 29 The current phase of illness was classified as newly diagnosed (pre-treatment or undergoing first-line treatment), stable disease (watch and wait or receiving maintenance treatment with no evidence of disease progression) or relapsed/progressive disease (second-line therapy or above, lack of response or progression on treatment or receiving palliative care). 30 Treatment details were recorded.
Measurements
Participants were followed up for a period of 8 months from baseline. They completed postal surveys every 2 months for a total of five assessments. Questionnaires that were administered assessed their generic or diseasespecific Quality of life and symptom burden. Trajectories of Health related quality of life and palliative care problems were determined from the Myeloma Patient Outcome Scale (MyPOS). 31 All questionnaires were selfreported. Comorbidity 32 and performance status 33 were first assessed directly from the patient in a clinical interview at the first clinic visit, using a standardised form. Comorbidity and all other clinical data were verified from the patient's clinical notes, again using a standardised form. Table 1 presents a short description of each outcome measure. The MyPOS is shown in Supplemental Figure S1 .
Statistical analysis
In order to detect a difference between subgroups in an independent, two-tailed t-test with 80% power, at a significance level of 5% and assuming a moderate effect size of 0.5-0.6 of change on the total MyPOS score, the estimated total sample size is 64-90. Allowing for attrition of 25%-30% over the course of 1 year, 113-117 patients needed to be recruited for the study.
Descriptive statistics (mean, standard deviation, percentages, medians and interquartile ranges for categorical data) were calculated. Prevalence of symptoms over time was determined as point prevalence with 95% confidence intervals (CIs) at each time point. Objective 1, determining change in Quality of life over time was established via latent class growth analysis. 39, 41 A trajectory class consists of a group of patients sharing a common course of Health related quality of life . The outcome that was modelled was the total MyPOS score for each patient. Latent class growth analysis analysis follows several analytical steps: 42 First, different growth functions (linear, quadratic) for modelling general slope growth were tested in a growth model without classes, to test which growth function would provide the best fit to the data. Second, the optimal number of classes was tested with within-class variance on growth parameters (slope) freely estimated. 42 Decisions on the number of classes of Health related quality of life trajectories were based on fit indices, in combination with clinical interpretability of the classes. 43 The mean class trajectories of the total MyPOS scores and all individual patient trajectories were plotted for each class.
To identify predictors for poor Health related quality of life , we ran ordinal logistic regression models with the proportional odds assumption. A poor or declining Health related quality of life outcome was defined as reporting a low level of Health related quality of life throughout the study period or reporting deteriorating MyPOS scores over the 8-month period, based on the classes of Health related quality of life trajectories found in the Latent class growth analysis. We first tested bivariate associations between the outcome variable and potential predictors (including demographic, clinical information, general symptom level and psychological symptoms) using nominal regression. Those predictors found to be significant at the 0.2 level in bivariate analyses were included in multivariable models.
The main analysis included non-missing data only. Missing data in Latent class growth analysis were addressed using full information maximum likelihood. 44 Regression analyses were repeated on multiple imputed data for sensitivity analyses. Three methods of imputation were used: (a) last observation carried forward, (b) imputation of the median value for each single item, stratified by disease stage of the individual and (c) multiple imputation. 45 Results from sensitivity analyses are reported in Supplemental Table S5 . All analyses were conducted using SPSS v22, 46 except for Latent class growth analysis which was conducted in MPlus 7.31. 47 All statistical tests used a 0.05 two-tailed alpha level of significance.
Results

Demographic and clinical characteristics
The mean age of the sample was 68.5 (SD 10.5), with 87 women (36.6%) and with average disease duration of 39 months (0-24 years, 95% CI: 34.2-44.1). A quarter of patients had lived longer than 5 years with myeloma (20.6%). According to the phase of illness, most were in a stable or plateau phase (53.1%). In all, 48.7% were in a later treatment phase, receiving second-line treatment or higher with 35.7% having received at least two lines of treatment. According to the ECOG performance status, one-quarter had at least moderate to severe disabilitywith 20.2% being unable to work or bedridden. The mean Charlson Comorbidity Index was 4.9 (95% CI: 4.7-5.1). The clinical characteristics are shown in Table 2. A total of 250 patients were recruited and consented into the study, with 238 patients completing questionnaires at baseline. In all, 199 participants completed time point 2 (83.6%), 171 completed time point 3 (71.8%), 150 completed time point 4 (63%) and 125 (52.5%) completed the last time point 5 questionnaire. Of the 113 patients lost to follow-up, 9 had died, 17 had been feeling too unwell to continue with the study, 2 had moved and 88 had given no reason to discontinue the study; 12 questionnaires had been lost in the mail (see Supplemental Figure S2 ). Table 3 presents the percentages of patients reporting each symptom as moderate, severe or overwhelming on the MyPOS and on the EORTC QLQ-C30 at each time point. At baseline, over half of patients reported fatigue (52.1%) and 40.3% reported moderate to overwhelming pain. Onethird of patients reported anxiety (31.1%). About onefourth of patients reported moderate to overwhelming breathlessness (20.2%), drowsiness (26.1%), tingling in the hands or feet (26.1%) and sleeping problems (24.4%). The frequency of moderate to overwhelming symptoms subsequently decreased over time with an increase seen at the last assessment, 8 months post-baseline.
Prevalence of common symptoms over time
Trajectories of Quality of life in Multiple myeloma
The adequacy of fit of several growth functions, including linear, piecewise and quadratic growth factors was tested 30 -item generic health-related quality of life questionnaire Five functional scales (physical, role, emotional, social, cognitive functioning), six symptom scales (fatigue, nausea/vomiting, pain, dyspnoea, constipation, appetite loss, sleeping problems, financial difficulties), one global health status/quality of life scale 4-point Likert-type scale (1 -not at all to 4 -Very much), except for two 7-point global health status/status/quality of life items Transformation of all scales to 0-100 scale. 58 High scores on functional scales and global quality of life scales represent high level of functioning/quality of life High scores on symptom scales represent a high symptom burden EORTC-QLQ-MY20 36 20-item add-on module of disease-specific symptoms and functional impact for multiple myeloma, added onto the EORTC-QLQ-C30 35 Two symptom subscales (disease symptoms and side effects of treatment), two functional subscales (body image and future perspectives) 4-point Likert-type scale (1 -not at all to 4 -Very much) Transformation of all scales to 0-100 High scores on functional scales represent high levels of functioning. High scores on symptom scales represent a high symptom burden Psychological status Hospital Anxiety and Depression Scale (HADS) 37 14-item measure to diagnose depression and anxiety in non-psychiatric hospital samples. Depression and anxiety subscale consist of 7 items each 4-point Likert-type scale from 0 (no problem) to 3 (maximum distress) Range of total score from 0 to 21 on each subscale. Cut-offs for the presence of clinically relevant anxiety or depression defined as ⩾8 on each subscale 34, 38 Mastery of illness Global Mastery Scale 40 7-item scale to measure the impact of disease and treatment on perception of self and perceived control/mastery over illness 5-point Likert-type scale ranging from 1 (strongly disagree) to 5 (strongly agree) 4 items need to be reversed scored to form a total score of 35 with the linear growth function providing the best fit in each model. Supplemental Table S3 contains the fit indicators for the number of latent classes in Quality of life trajectories in Latent class growth analysis analysis. Across the models, a 4-class and 5-class solution worked best with values for the Bayesian information criterion (BIC) and Akaike information criterion (AIC) decreasing for these models compared to models with smaller or higher numbers of classes (see Supplemental Table S3 ). The four-class solution was chosen based on the better BIC, entropy and likelihood test values, better clinical interpretability and better class group sizes than seen in the 5-class solution.
A total of 216 participants contributed enough data at all time points to enter trajectory analysis. Figure 1 shows the four trajectories of Quality of life and palliative care concerns. The first trajectory (n = 57, 26.4%) followed a pattern of slightly improving Quality of life, with an initial medium level of symptoms and problems (M = 36.7, SD = 10.8 at T1), and subsequently decreasing over 8 months to a lower level of symptoms (M = 28.6, SD = 10.1 at T5). Most of the sample (n = 122, 56.5%) fell under a pattern of stable, good Quality of life, starting from an already high Quality of life baseline level at T1 (M = 14.9, SD = 7.6) and showing only minute differences over the 8 months follow-up (M = 15.1, SD = 8.5 at T5). The third class (n = 24, 11.1%), termed stable, poor Quality of life, was characterised by generally high symptom burden/palliative care concerns throughout the follow-up period (M = 55.1, SD = 9.9 at T1 to M = 53.1, SD = 13.5 at T5) and experiencing a much lower baseline Quality of life than all other classes. In the fourth class (n = 13, 6%), termed deteriorating Quality of life, participants experienced relatively 
Sample characteristics of MyPOS trajectories
Multinomial regression models showed significant associations between trajectory class and the demographic factors occupational status and the clinical characteristics ECOG performance status and intensity of prior treatments. More participants in class 1, slightly improving Quality of life, and class 2, stable good Quality of life, were not working than expected. Participants with a trajectory of poor or deteriorating Quality of life (classes 3 and 4) were experiencing a poorer ECOG performance status, but had less intensive treatments than expected, compared to members of other classes (see Supplemental Table S4 ) . 
Regression analysis: predictors of poor and deteriorating Quality of life
For determining which baseline characteristics predict a poor outcome in Multiple myeloma patients, we first entered those variables found in univariate regression analysis to be significant into the multivariable model. The model was then trimmed to contain only those significant in multivariable analysis and adjusted for general symptom level (total number out of 15 symptoms experienced by each participant; see Table 4 ). Experiencing a trajectory of poor or deteriorating Quality of life was predicted by baseline pain (odds ratio Compared to the reference group of ECOG performance status 0 (fully active), participants with poor or deteriorating Quality of life had lower odds of being in the ECOG performance status group 2 (ambulatory but unable to carry out work activities) (OR = 0.2, 95% CI: 0.1-0.9, p = 0.042).
Discussion
Main findings
This study is the first to describe and compare the longitudinal patterns of change in Quality of life and palliative care concerns in patients with Multiple myeloma. We successfully investigated the heterogeneity in the course of Health related quality of life trajectories across an 8-month study period and determined four classes of trajectories. To capture the breadth of the Quality of life experience of Multiple myeloma patients, we did not restrict our sample to a specific group of patients on chemotherapy or newly diagnosed patients eligible for first-line treatment. Within all Quality of life trajectories, the two largest classes (class 1, 26.4%, and class 2, 56.5%) were characterised by improving and stable, good Health related quality of life . Notably, Multiple myeloma patients in class 1 showed a much lower intercept than patients in class 2, indicating that they experienced poor Health related quality of life at the beginning of the observation period and then substantially improved over the course of 8 months. The initial intercept of class 2 was much higher, suggesting that this group started with a better Quality of life and remained relatively stable in the next months. In comparison, patients in classes 3 (11.1%) and 4 (6%) experienced either a poor Quality of life throughout the 8-month observation period or, as in class 4, showed the most severe trajectory of deteriorating Quality of life. Class membership was not associated with stage of disease. Thus, experiencing a stable trajectory of Quality of life or a course of improving Quality of life was not associated with being in a stable, treatment-free interval or with recovering from first-or second-line treatment. Rather, members of trajectory classes 3 and 4 were those with higher general symptom levels, a higher pain level, a poor ECOG performance status (unable to carry out work activities) and with clinically relevant levels of anxiety and depression.
Strengths and limitations
Our observational study is based on a large, representative sample of patients with Multiple myeloma that were sampled from different settings and at different stages of their disease. This lends greater representativeness to the findings than possible in treatment-defined samples 48 or clinical research samples that are usually composed of more carefully selected individuals and oversample younger patients with less comorbid disease. 49 The drawback of this methodology is that patients were consecutively enrolled in the participating centres, resulting in a convenience sample. Another drawback is the comparably higher heterogeneity in the patient group, with type of treatment and age possibly acting as confounders. However, both treatment history and age were not found to be significantly associated with the type of Health related quality of life trajectory of the patient. Further research could start to validate these trajectories in more narrowly defined samples of Multiple myeloma. The outpatient setting and possible gatekeeping from recruiting staff might have resulted in a higher proportion of patients with stable disease and a lower symptom burden having been included in this study. This selection bias will have been aggravated by the eligibility criteria. However, this bias could only be mitigated via a registry-based sampling approach, 10 which was not feasible in this study. The group for which predictors was modelled, consisting of patients with poor or deteriorating Quality of life, was comparably small to the larger classes of improving and stable, good Quality of life. This will have reduced analytical power. 43 Small numbers in these two classes may have been a reflection of the substantial drop-out we phased over the course of 8 months.
Only 50% patients remained in the study and most did not give reasons for drop-out, but high treatment or disease burden was suspected. Future studies should reduce assessment burden in participants. Latent class growth models for Health related quality of life only included baseline predictors. Time-varying covariates were not included in the model due to the comparably small sample size. Other covariates that were not included in the model may have influenced the Health related quality of life trajectories. In particular, information on response to treatment 22 and important biomedical variables such as albumin, C-reactive protein, 49 haemoglobin levels, 50 and possible cytokines 51, 52 might have altered the number and OR yielded in the logistic regression analysis. Future research needs to investigate the relationship between patient-reported outcomes like symptoms and QOL and these biomedical variables and their respective strength for indicating deteriorating disease and the potential need for palliative care involvement. Findings of this study need to be validated in larger samples and specifically in a study with a longer follow-up period during which more patients progress through intervals of high-dose treatment and stable, treatment-free phases to see the evolution of Quality of life.
What this study adds
Longitudinal studies are rare in Multiple myeloma. Most of the evidence on Quality of life is presented as secondary endpoint data in clinical trials or in longitudinal studies of patients receiving haematopoietic stem cell transplant populations. [51] [52] [53] [54] Only one longitudinal observational study using a population perspective could be identified. 10 Mols et al. 10 assessed myeloma-specific Quality of life at two time points with the EORTC QLQ-C30 and its myeloma MY20 module. They described a generally poor Quality of life compared to an age-and gender-matched normative sample. Worsening of symptoms such as pain, peripheral neuropathy, drowsiness, but also psychosocial problems such as worries about the future and about dying, was observed. However, in this registry-based study only two measurement points, 1 year apart, were used to evaluate the mean trajectory of Quality of life. Studies of salvage cryotherapy (SCT) populations, 51-54 on the contrary, report an increase in Quality of life over the course of the first 2 years after transplantation. Only depression and life satisfaction have been reported as persistent areas of concern. 53 In our study, we observed a large heterogeneity in the Quality of life trajectories that was not captured in the mean change in Quality of life over time. Compared to the available longitudinal evidence, our findings highlight that within an average trajectory of stability or improvement, subgroups of patients exist whose Quality of life trajectories differ substantially from the overall course. The logistic regression analysis identified five variables, general symptom level, pain, anxiety, depression and ECOG performance status, as significant predictors of poor or deteriorating Quality of life in Multiple myeloma. This result is similar to multivariable regression analyses in two recent, observational cross-sectional studies in myeloma. 55, 56 Jordan and co-authors determined symptom burden in 154 Multiple myeloma patients. 56 Fatigue and bone pain were the most frequent symptoms and were strongly associated with global Quality of life, as were depression, general symptom level, disease duration and currently being on treatment. Also, a study of stable but advanced stage Multiple myeloma patients identified pain and fatigue as the most frequent symptoms, impacting negatively on physical functioning. 55 Similarly, these studies did not identify clinical factors such as comorbidities or type of treatment as significantly associated factors for Quality of life. The importance of physical functioning, symptoms and psychosocial distress and their higher predictive power compared to disease parameters have been demonstrated in three prognostic studies. [26] [27] [28] For example, psychosocial Quality of life scales were associated with overall survival, whereas none of the disease parameters (ISS stage, creatinine, LDH, M-protein level and albumin level) explained a substantial proportion in the overall variability of Quality of life parameters. 27 
Conclusion
Despite recent guidelines pleading the access of haematological cancer patients to palliative care services due to the high symptom burden in this group, 10,11 these patients, particularly more chronic haematological malignancies such as Multiple myeloma, miss out on Specialist palliative care. [19] [20] [21] Our findings demonstrate that in order to reach haematological cancer patients early enough, the model of care needs to change. The result of a subgroup of patients consistently experiencing poor or deteriorating Quality of life calls for early identification of these patients and early integration of palliative care alongside anti-myeloma treatment regimens. 16 In particular, possible targets that indicate suitability for palliative care involvement are patients that experience a high general symptom level, high levels of psychosocial distress, pain and low physical functioning. In order to identify these patients in clinical practice, routine monitoring of symptoms and Quality of life is warranted.
